{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T23:05:25Z","timestamp":1784243125940,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the \u201c1+X\u201d program for Clinical Competency enhancement-Clinical Research Incubation Project and the Second Hospital of Dalian Medical University","award":["2022LCYJYB08"],"award-info":[{"award-number":["2022LCYJYB08"]}]},{"name":"\u201c1+X\u201d program for Clinical Competency enhancement\u2013Clinical Research Incubation Project and the Second Hospital of Dalian Medical University","award":["2022LCYJZD02"],"award-info":[{"award-number":["2022LCYJZD02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Prostate cancer (PCa) ranks as the second most common malignancy and the fifth leading cause of cancer-related deaths among men. A critical challenge lies in accurately identifying those patients at high risk for transitioning rapidly from hormone-sensitive PCa (HSPC) to lethal castration-resistant PCa (CRPC). In our study, we employed a multiomics approach involving bioinformatics analysis on datasets GSE2443 and GSE35988, along with proteomics studies, to discover that cysteine- and glycine-rich protein 1 (CSRP1) expression significantly impacts the progression of HSPC. This hypothesis was substantiated through experiments using PC3 and LNCaP prostate cancer cells, where we conducted scratch assays and apoptosis assays, all of which confirmed CSRP1\u2019s role in suppressing tumor growth. Furthermore, we elucidated the inhibitory effect of CSRP1 on tumors by performing xenograft experiments on castrated mice models. To solidify these findings in a clinical context, we constructed a nomogram model integrating CSRP1\u2019s immunohistochemistry data and clinical parameters from an actual patient cohort with HSPC. This model revealed that low CSRP1 expression indeed promotes the advancement towards CRPC. In conclusion, the level of CSRP1 expression can serve as a valuable biomarker for clinicians to predict disease progression in their patients. It has the potential to guide personalized clinical management and decision-making strategies, thereby contributing to more effective and targeted treatment approaches for HSPC patients.<\/jats:p>","DOI":"10.1186\/s12935-025-03708-y","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T11:21:06Z","timestamp":1740396066000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Identification of CSRP1 as novel biomarker for hormone-sensitive prostate cancer by the combination of clinical and functional research"],"prefix":"10.1186","volume":"25","author":[{"given":"Chenxi","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"issue":"3","key":"3708_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"issue":"2","key":"3708_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. Cancer J Clin. 2016;66(2):115\u201332.","journal-title":"Cancer J Clin"},{"issue":"5","key":"3708_CR3","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.eururo.2011.08.024","volume":"60","author":"A Bjartell","year":"2011","unstructured":"Bjartell A. Circulating tumour cells as surrogate biomarkers in castration-resistant prostate cancer trials. Eur Urol. 2011;60(5):905\u20137.","journal-title":"Eur Urol"},{"issue":"2","key":"3708_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ncpuro1296","volume":"6","author":"WP Harris","year":"2009","unstructured":"Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in Understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6(2):76\u201385.","journal-title":"Nat Clin Pract Urol"},{"issue":"11","key":"3708_CR5","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Chemohormonal therapy in metastatic Hormone-Sensitive prostate cancer: Long-Term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncology: Official J Am Soc Clin Oncol. 2018;36(11):1080\u20137.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"5","key":"3708_CR6","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, \u00d6zg\u00fcro\u011flu M, Ye D, Feyerabend S, Protheroe A, Sulur G, Luna Y, Li S, Mundle S, Chi KN. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686\u2013700.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3708_CR7","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/nrm1499","volume":"5","author":"JL Kadrmas","year":"2004","unstructured":"Kadrmas JL, Beckerle MC. The LIM domain: from the cytoskeleton to the nucleus. Nat Rev Mol Cell Biol. 2004;5(11):920\u201331.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"3708_CR8","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1083\/jcb.119.6.1573","volume":"119","author":"I Sadler","year":"1992","unstructured":"Sadler I, Crawford AW, Michelsen JW, Beckerle MC. Zyxin and cCRP: two interactive LIM domain proteins associated with the cytoskeleton. J Cell Biol. 1992;119(6):1573\u201387.","journal-title":"J Cell Biol"},{"issue":"9","key":"3708_CR9","first-page":"2317","volume":"8","author":"R Weiskirchen","year":"1993","unstructured":"Weiskirchen R, Bister K. Suppression in transformed avian fibroblasts of a gene (crp) encoding a cysteine-rich protein containing LIM domains. Oncogene. 1993;8(9):2317\u201324.","journal-title":"Oncogene"},{"issue":"3","key":"3708_CR10","first-page":"2730","volume":"20","author":"F Xu","year":"2020","unstructured":"Xu F, Zhang P, Yuan M, Yang X, Chong T. Bioinformatic screening and identification of downregulated hub genes in adrenocortical carcinoma. Experimental Therapeutic Med. 2020;20(3):2730\u201342.","journal-title":"Experimental Therapeutic Med"},{"issue":"1","key":"3708_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s12672-022-00508-y","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Ma J, Xu C, Wang L, Yao Y, Wang X, Zi T, Bian C, Wu D, Wu G. Identification of hub genes predicting the development of prostate cancer from benign prostate hyperplasia and analyzing their clinical value in prostate cancer by bioinformatic analysis. Discover Oncol. 2022;13(1):54.","journal-title":"Discover Oncol"},{"key":"3708_CR12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1752-0509-2-106","volume":"2","author":"A Fujita","year":"2008","unstructured":"Fujita A, Gomes LR, Sato JR, Yamaguchi R, Thomaz CE, Sogayar MC, Miyano S. Multivariate gene expression analysis reveals functional connectivity changes between normal\/tumoral prostates. BMC Syst Biol. 2008;2:106.","journal-title":"BMC Syst Biol"},{"key":"3708_CR13","doi-asserted-by":"crossref","unstructured":"Wang L, Liu X, Yue M, Liu Z, Zhang Y, Ma Y, Luo J, Li W, Bai J, Yao H, Chen Y, Li X, Feng D, Song X. Identification of hub genes in bladder cancer based on weighted gene co-expression network analysis from TCGA database. Cancer Rep (Hoboken N J), 5(9), e1557 (2022).","DOI":"10.1002\/cnr2.1557"},{"issue":"5","key":"3708_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.clgc.2023.06.011","volume":"21","author":"Y Luo","year":"2023","unstructured":"Luo Y, Chen D, Xing XL. Comprehensive analyses revealed eight immune related signatures correlated with aberrant methylations as prognosis and diagnosis biomarkers for kidney renal papillary cell carcinoma. Clin Genitourin Cancer. 2023;21(5):537\u201345.","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"3708_CR15","doi-asserted-by":"publisher","first-page":"100613","DOI":"10.1016\/j.mcpro.2023.100613","volume":"22","author":"C Pan","year":"2023","unstructured":"Pan C, He Y, Wang H, Yu Y, Li L, Huang L, Lyu M, Ge W, Yang B, Sun Y, Guo T, Liu Z. Identifying patients with rapid progression from Hormone-Sensitive to Castration-Resistant prostate cancer: A retrospective study. Mol Cell Proteomics: MCP. 2023;22(9):100613.","journal-title":"Mol Cell Proteomics: MCP"},{"issue":"4","key":"3708_CR16","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1161\/ATVBAHA.109.200741","volume":"30","author":"B Lilly","year":"2010","unstructured":"Lilly B, Clark KA, Yoshigi M, Pronovost S, Wu ML, Periasamy M, Chi M, Paul RJ, Yet SF, Beckerle MC. Loss of the serum response factor cofactor, cysteine-rich protein 1, attenuates Neointima formation in the mouse. Arterioscler Thromb Vasc Biol. 2010;30(4):694\u2013701.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"3708_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s11033-009-9632-1","volume":"37","author":"X Xu","year":"2010","unstructured":"Xu X, Qiu H, Du ZQ, Fan B, Rothschild MF, Yuan F, Liu B. Porcine CSRP3: polymorphism and association analyses with meat quality traits and comparative analyses with CSRP1 and CSRP2. Mol Biol Rep. 2010;37(1):451\u20139.","journal-title":"Mol Biol Rep"},{"issue":"24","key":"3708_CR18","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1097\/00029330-200812020-00003","volume":"121","author":"CZ Zhou","year":"2008","unstructured":"Zhou CZ, Qiu GQ, Wang XL, Fan JW, Tang HM, Sun YH, Wang Q, Huang F, Yan DW, Li DW, Peng ZH. Screening of tumor suppressor genes on 1q31.1-32.1 in Chinese patients with sporadic colorectal cancer. Chin Med J. 2008;121(24):2479\u201386.","journal-title":"Chin Med J"},{"issue":"6","key":"3708_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.gpb.2017.08.002","volume":"15","author":"L Gao","year":"2017","unstructured":"Gao L, Ye M, Lu X, Huang D. Hybrid method based on information gain and support vector machine for gene selection in Cancer classification. Genom Proteom Bioinform. 2017;15(6):389\u201395.","journal-title":"Genom Proteom Bioinform"},{"key":"3708_CR20","doi-asserted-by":"publisher","first-page":"1028404","DOI":"10.3389\/fimmu.2023.1028404","volume":"14","author":"ZJ Zhang","year":"2023","unstructured":"Zhang ZJ, Huang YP, Liu ZT, Wang YX, Zhou H, Hou KX, Tang JW, Xiong L, Wen Y, Huang SF. Identification of immune related gene signature for predicting prognosis of cholangiocarcinoma patients. Front Immunol. 2023;14:1028404.","journal-title":"Front Immunol"},{"issue":"5","key":"3708_CR21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00109-009-0446-3","volume":"87","author":"F Conrad","year":"2009","unstructured":"Conrad F, Zhu X, Zhang X, Chalkley RJ, Burlingame AL, Marks JD, Liu B. Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion. J Mol Med. 2009;87(5):507\u201314.","journal-title":"J Mol Med"},{"issue":"1","key":"3708_CR22","doi-asserted-by":"publisher","first-page":"8838","DOI":"10.1038\/s41598-019-44991-w","volume":"9","author":"M Ghashghaei","year":"2019","unstructured":"Ghashghaei M, Niazi TM, Aguilar-Mahecha A, Klein KO, Greenwood CMT, Basik M, Muanza TM. Identification of a radiosensitivity molecular signature induced by enzalutamide in Hormone-sensitive and Hormone-resistant prostate Cancer cells. Sci Rep. 2019;9(1):8838.","journal-title":"Sci Rep"},{"issue":"1","key":"3708_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3233\/CBM-200939","volume":"31","author":"Y Yan","year":"2021","unstructured":"Yan Y, Mao X, Zhang Q, Ye Y, Dai Y, Bao M, Zeng Y, Huang R, Mo Z. Molecular mechanisms, immune cell infiltration, and potential drugs for prostate cancer. Cancer Biomark A. 2021;31(1):87\u201396.","journal-title":"Cancer Biomark A"},{"issue":"11","key":"3708_CR24","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s11912-022-01323-y","volume":"24","author":"G Napoli","year":"2022","unstructured":"Napoli G, Arcangeli S, Fionda B, Munoz F, Tebano U, Durante E, Tucci M, Bortolus R, Muraro M, Rinaldi G, Luca N, Fiorica F. A systematic review and a Meta-analysis of randomized controlled trials\u2019 control groups in metastatic Hormone-Sensitive prostate Cancer (mHSPC). Curr Oncol Rep. 2022;24(11):1633\u201344.","journal-title":"Curr Oncol Rep"},{"issue":"11","key":"3708_CR25","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1002\/cncr.32039","volume":"125","author":"PC Barata","year":"2019","unstructured":"Barata PC, Sartor AO. Metastatic castration-sensitive prostate cancer: abiraterone, docetaxel, or\u2026. Cancer. 2019;125(11):1777\u201388.","journal-title":"Cancer"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03708-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-03708-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03708-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T11:21:17Z","timestamp":1740396077000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-025-03708-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3708"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-03708-y","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"9 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was accepted by the ethical committee of the Second Hospital of Dalian Medical University complying with the Declaration of Helsinki (approval number: 2020019), all patients submitted written informed consent prior to analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}